Elicio Therapeutics, Inc. ELTX
Elicio Therapeutics, Inc. (Nasdaq: ELTX) is an oncology drug developer. Its lead program, camupepimut (ELI-002 7P), is in Phase 3 for mKRAS-positive pancreatic ductal adenocarcinoma (PDAC). Its next catalyst on record is camupepimut combination study: Phase 1 study initiation in combination with daraxonrasib with or without nivolumab in metastatic mKRAS pancreatic cancer (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: camupepimut combination study — Phase 1 study initiation in combination with daraxonrasib with or without nivolumab in metastatic mKRAS pancreatic cancer (Q4 2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| camupepimut (ELI-002 7P) | mKRAS-positive PDAC (adjuvant) | peptide-based immunotherapy | Phase 3 |
| camupepimut combination study | metastatic mKRAS PDAC | peptide-based immunotherapy + small molecule + anti-PD-1 | Phase 1 |
| ELI-002 2P | mKRAS-driven solid tumors (post-surgery) | peptide-based immunotherapy | Phase 1 |
| ELI-007 | mutant BRAF-driven cancers | peptide-based immunotherapy | Pre-clinical |
| ELI-008 | mutated TP53-expressing cancers | peptide-based immunotherapy | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
- Astrazeneca PLC AZN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Revolution Medicines, Inc. RVMD
- Genmab A/S GMAB
- BioNTech SE BNTX
- Guardant Health, Inc. GH
- Exelixis, Inc. EXEL
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.